Weiwei Cao, PhD
Gastroenterology · Cedar Park, TXNPI 1992987283
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,335 of the $4,093 with a category attached, or 81.5%. Astrazeneca UK Limited accounts for 81.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $1,758 and has fallen 96.0% since, to $70 in 2025.
Across 27 payments — averaging $151.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$3K
- Intercept Pharmaceuticals, Inc.$240
- E.r. Squibb & Sons, L.L.C.$133
- Pfizer$133
- AbbVie$98
- Bristol Myers Squibb$55
- plus $100 from 5 others
What the payments were for
- Consulting fees$3,33581%
- Food & beverage$75819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 2 | $3,335 |
| Intercept Pharmaceuticals, Inc. | 3 | $240 |
| E.r. Squibb & Sons, L.L.C. | 1 | $133 |
| Pfizer | 8 | $133 |
| AbbVie | 4 | $98 |
| Bristol Myers Squibb | 3 | $55 |
| Merck | 1 | $28 |
| Johnson & Johnson | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Romark Laboratories, LC | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,093 in reported general payments places this provider in the 55th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Esomeprazole Magnesium | 15 | $1,687 |
| Omeprazole | 83 | $709 |
| Pantoprazole Sodium | 27 | $318 |
| Ondansetron OdtOndansetron | 14 | $61 |
| Dicyclomine Hcl | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Cedar Park
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Nadege GunnWaco$933K
- Brooks CashHouston$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.